The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.

Détails

ID Serval
serval:BIB_44E162F82DC6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
Périodique
Lancet. Infectious Diseases
Auteur(s)
Schallig HDFH, Van den Broek I, Van Vugt M, Ibrahim ML, Falade CO, Meremikwu M, Gil JP, Karema C, Ba MS, Faye B, Faye O, Gaye O, Ndiaye JL, Pene M, Sow D, Sylla K, Tine RCK, Penali LK, Barnes KI, Workman LJ, Barnes KI, Workman LJ, Bassat Q, Gonzalez R, Menendez C, Mueller I, Lima A, Adam I, Gadalla NB, Malik EFM, Bjorkman A, Gil JP, Martensson A, Ngasala BE, Ursing J, Rombo L, Aliu P, Duparc S, Filler S, Genton B, Hodel EM, Olliaro P, Abdulla S, Kamugisha E, Ngasala BE, Premji Z, Shekalaghe SA, Shekalaghe SA, Ashley EJ, Carrara VI, McGready R, Nosten F, Ashley EA, Faiz AM, Lee SJ, White NJ, Carrara VI, Dondorp AM, Smith JJ, D'Alessandro U, Tarning J, Achan J, Bukirwa H, Yeka A, Arinaitwe E, Staedke SG, Kamya MR, Kironde F, Nabasumba C, Bousema T, Drakeley CJ, Gadalla NB, Oguike M, Sutherland CJ, Checchi F, Dahal P, Flegg JA, Guerin PJ, Moreira C, Newton PJ, Nsanzabana C, Price RN, Sibley CH, Stepniewska K, Tarning J, Dahal P, Dondorp AM, Flegg JA, Guerin PJ, Lee SJ, Marsh K, McGready R, Moreira C, Newton PN, Nosten F, Nsanzabana C, Olliaro P, Price RN, Tarning J, White NJ, Gething PW, Hay SI, Greenwood B, Hodel EM, Ward SA, Staedke SG, Van den Broek I, Winstanley PA, Dorsey G, Greenhouse B, Rosenthal PJ, Gadalla NB, Gil JP, Grivoyannis A, Hamed K, Hwang J, Kachur PS, Hwang J, Sibley CH, Nambozi M
Collaborateur(s)
Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group, Anstey NM;, Price RN;, Davis TME;, Karunajeewa HA;, Mueller I;, Karunajeewa HA;, D'Alessandro U;, Massougbodji A;, Nikiema F;, Ouedraogo JB;, Tinto H;, Zongo I;, Ouedraogo JB;, Tinto H;, Same-Ekobo A;, Kone M;, Menan H;, Toure AO;, Yavo W;, Yavo W;, Kofoed PE;, Alemayehu BH;, Jima D;, Baudin E;, Espie E;, Nabasumba C;, Pinoges L;, Schramm B;, Cot M;, Deloron P;, Faucher JF;, Cot M;, Deloron P;, Faucher JF;, Faucher JF;, Guthmann JP;, Lell B;, Borrmann S;, Lell B;, Adjei GO;, Kofoed PE;, Ursing J;, Tjitra E;, Borrmann S;, Marsh K;, Peshu J;, Juma E;, Ogutu BR;, Omar SA;, Sawa P;, Talisuna AO;, Talisuna AO;, Khanthavong M;, Mayxay M;, Newton PN;, Mayxay M;, Piola P;, Djimde AA;, Doumbo OK;, Fofana B;, Sagara I;, Bassat Q;, Gonzalez R;, Menendez C;, Smithuis F;, Smithuis F;, Bousema T;, Kager PA;, Mens PF;
ISSN
1474-4457 (Electronic)
ISSN-L
1473-3099
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
15
Numéro
6
Pages
692-702
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish Document Type: Review
Résumé
BACKGROUND: Artemether-lumefantrine is the most widely used artemisinin-based combination therapy for malaria, although treatment failures occur in some regions. We investigated the effect of dosing strategy on efficacy in a pooled analysis from trials done in a wide range of malaria-endemic settings.
METHODS: We searched PubMed for clinical trials that enrolled and treated patients with artemether-lumefantrine and were published from 1960 to December, 2012. We merged individual patient data from these trials by use of standardised methods. The primary endpoint was the PCR-adjusted risk of Plasmodium falciparum recrudescence by day 28. Secondary endpoints consisted of the PCR-adjusted risk of P falciparum recurrence by day 42, PCR-unadjusted risk of P falciparum recurrence by day 42, early parasite clearance, and gametocyte carriage. Risk factors for PCR-adjusted recrudescence were identified using Cox's regression model with frailty shared across the study sites.
FINDINGS: We included 61 studies done between January, 1998, and December, 2012, and included 14 327 patients in our analyses. The PCR-adjusted therapeutic efficacy was 97·6% (95% CI 97·4-97·9) at day 28 and 96·0% (95·6-96·5) at day 42. After controlling for age and parasitaemia, patients prescribed a higher dose of artemether had a lower risk of having parasitaemia on day 1 (adjusted odds ratio [OR] 0·92, 95% CI 0·86-0·99 for every 1 mg/kg increase in daily artemether dose; p=0·024), but not on day 2 (p=0·69) or day 3 (0·087). In Asia, children weighing 10-15 kg who received a total lumefantrine dose less than 60 mg/kg had the lowest PCR-adjusted efficacy (91·7%, 95% CI 86·5-96·9). In Africa, the risk of treatment failure was greatest in malnourished children aged 1-3 years (PCR-adjusted efficacy 94·3%, 95% CI 92·3-96·3). A higher artemether dose was associated with a lower gametocyte presence within 14 days of treatment (adjusted OR 0·92, 95% CI 0·85-0·99; p=0·037 for every 1 mg/kg increase in total artemether dose).
INTERPRETATION: The recommended dose of artemether-lumefantrine provides reliable efficacy in most patients with uncomplicated malaria. However, therapeutic efficacy was lowest in young children from Asia and young underweight children from Africa; a higher dose regimen should be assessed in these groups.
FUNDING: Bill & Melinda Gates Foundation.
Pubmed
Web of science
Création de la notice
12/06/2015 16:21
Dernière modification de la notice
20/08/2019 13:49
Données d'usage